This is the authors' abstract. We don't add key points for this paper.
INTRODUCTION: Relugolix is a potent nonpeptide gonadotropin-releasing hormone receptor antagonist. This dose-finding study explored the ability of relugolix to decrease the heavy menstrual bleeding (HMB) associated with uterine fibroids (UF). METHODS: This randomized, double-blind, placebo-controlled, phase 2 study was designed to evaluate relugolix 10 mg, 20 mg and 40 mg administered orally once daily for 12 weeks in Japanese women with UF and HMB defined as a Pictorial Blood Loss Assessment Chart (PBAC) score of at least 120. The primary endpoint was the proportion of women with a total PBAC score of less than 10 from Week 6 to 12. Secondary endpoints included the proportion of women with amenorrhea, and myoma and uterine volumes. RESULTS: Patients (N = 216) were randomized to placebo or one of three relugolix groups. The proportion of patients with PBAC score of less than 10 from Week 6 to 12 was 0% in placebo group, and 20.8%, 43.6% and 83.6% in relugolix 10 mg, 20 mg and 40 mg groups (P < 0.001 vs placebo).74% of patients in relugolix 40 mg group achieved amenorrhea, and a dose-dependent decrease in myoma and uterine volumes were observed. The incidence of headache, metrorrhagia, menorrhagia, and hot flush were more than 10% higher in relugolix 20 mg and 40 mg groups than in placebo group; these AEs were mild or moderate in severity. CONCLUSION: Treatment with relugolix showed significant dose-dependent decreases in menstrual blood loss compared with placebo and was generally well-tolerated with AEs consistent with the drug’s mechanism of action.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Hoshiai et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: